John M Abraham

US Patent:

8435490, May 7, 2013

Filed:

Jun 4, 2008

Appl. No.:

12/664302

Inventors:

John Martin Abraham - Woodbine MD, US
Stephen J. Meltzer - Lutherville MD, US

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

A61K 51/00
A61M 36/14

US Classification:

424 169, 424 111, 424 165, 424 181, 424 185, 424 189

Abstract:

Cancers are extremely heterogeneous in terms of the frequency and types of mutations present in different malignant tumors. Thus, it is likely that uniform clinical treatment is not optimal for all patients, and that the development of individualized therapeutic regimens may be beneficial. Multiple, unique small peptides bind to cell lines derived from different colon adenocarcinomas. Within two hours of contact, the colorectal cancer cells are able to transfer a P radioisotope from the small peptides to cellular proteins; the transfer occurs at a substantially higher rate than in the colorectal cancer cells than in cell lines derived from other cancers or from normal tissues.

US Patent:

20220356532, Nov 10, 2022

Filed:

Oct 26, 2020

Appl. No.:

17/771772

Inventors:

- Baltimore MD, US
Ke Ma - Hanover MD, US
Yulan Cheng - Ellicott City MD, US
John Martin Abraham - Woodbine MD, US

International Classification:

C12Q 1/6886

Abstract:

The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods useful for detecting and treating esophageal cancer. In a specific embodiment, a method for identifying a subject having esophageal adenocarcinoma (EAC) comprises (a) extracting genomic DNA from a sample obtained from the subject; (b) performing a conversion reaction on the genomic DNA in vitro to convert unmethylated cytosine to uracil by deamination; and (c) detecting nucleic acid methylation of one or more genes in the converted genomic DNA, wherein detecting nucleic acid methylation identifies the subject as having EAC. The one or more genes can comprise ABCB1, BMP3, COL23A1, FBN1, FADS1 and PRDM2. In a more specific embodiment, the one or more genes comprise at least three of ABCB1, BMP3, COL23A1, FBN1, FADS1 and PRDM2.

US Patent:

20220195535, Jun 23, 2022

Filed:

Apr 16, 2020

Appl. No.:

17/604255

Inventors:

- Baltimore MD, US
Ke Ma - Hanover MD, US
Yulan Cheng - Ellicott City MD, US
John Martin Abraham - Woodbine MD, US

International Classification:

C12Q 1/6886

Abstract:

The present invention relates to the field of cancer. More specifically, the present invention provides compositionsand methods useful for detecting and treating esophageal cancer. In a specific embodiment, a method for identifying a subject having esophageal squamous cell carcinoma (ESCC) comprises (a) extracting genomic DNA from a sample obtained from the subject; (b)performing a conversion reaction on the genomic DNA in vitro to convert unmethylated cytosine to uracil by deamination; and (c)detecting nucleic acid methylation of one or more genes in the converted genomic DNA, wherein detecting nucleic acid methylation e identifies the subject as having ESCC. The one or more genes can comprise ZNF542, ZNF132, cg20655070, TAC1 and SLC35F1. In amore specific embodiment, the one or more genes comprise ZNF542 and ZNF132 and can further comprise detecting the nucleic acid N methylation of one or more of cg20655070, TAC1 and SLC35F1.